Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Member Level
Re: None
Thursday, February 16, 2023 12:51:47 PM
Post#
25491
of 25491
Halberd Corporation Announces Breakthrough in Candida auris Treatment
Press Release | 02/13/2023
Halberd Demonstrates Eradication of Candida Auris Fungus in as little as 5 minutes.
JACKSON CENTER, PA / ACCESSWIRE / February 13, 2023 / Halberd Corporation (OTC PINK:HALB) a leading provider of innovative healthcare solutions, is proud to announce a major breakthrough in the development of a treatment for Candida auris infections. Candida auris is one of the antibiotic resistant infectious pathogens sent by the CDC (Centers for Disease Control and Prevention) to Youngstown State University (YSU) for testing. With its scientific partner, Halberd has developed a novel, extracorporeal method of successfully eradicating the multidrug-resistant pathogen using a tuned laser in conjunction with metallic nanoparticles conjugated to a patent-pending non-neutralizing, high-affinity antibody. Halberd previously demonstrated its patent-pending extracorporeal laser eradication by successfully eliminating Escherichia coli and antibiotic resistant strains of Gram-Negative bacteria.
Candida auris is a serious and growing public health threat. It is a multidrug-resistant fungal pathogen that can cause serious infections and is associated with high mortality rates, particularly in immunocompromised patients.
See CBS News report:
"Halberd's innovative approach offers a highly effective solution for treating Candida auris infections and could help to reduce the spread of this pathogen in healthcare settings," stated Dr. Cooper, Professor, Department of Chemical and Biological Sciences at Youngstown State University. "This approach potentially offers a highly effective solution for treating this serious health concern, and we are committed to bring this treatment to patients in need."
William A. Hartman, Halberd's Chairman, President & CEO commented, "An effective treatment of Candida auris would help to address the growing public health threat posed by multidrug-resistant pathogens and the increasing frequency of fungal infections. Halberd's patented breakthrough technology has shown potentially universal capacity to eradicate pathogens. In particular, our patent protected methodologies successfully eradicated in vitro viruses (SARS-CoV-2), inflammatory cytokines, excitatory neurotransmitters (glutamate), antibiotic-resistant bacteria, and now deadly Candida auris fungus. Halberd's patent protected technologies are designed to have a major impact on medical treatments worldwide and lead to improved patient outcomes, fewer deaths, greater longevity and reduced healthcare costs. Halberd's process is effective in minutes, NOT lengthy treatment protocols with potentially harmful and too often ineffectual antibiotics."
To get the latest news on Halberd's exciting developments, including our ongoing disease eradication accomplishments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/)
For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
0
Halberd Corporation Announces Breakthrough in Candida auris Treatment
Press Release | 02/13/2023
Halberd Demonstrates Eradication of Candida Auris Fungus in as little as 5 minutes.
JACKSON CENTER, PA / ACCESSWIRE / February 13, 2023 / Halberd Corporation (OTC PINK:HALB) a leading provider of innovative healthcare solutions, is proud to announce a major breakthrough in the development of a treatment for Candida auris infections. Candida auris is one of the antibiotic resistant infectious pathogens sent by the CDC (Centers for Disease Control and Prevention) to Youngstown State University (YSU) for testing. With its scientific partner, Halberd has developed a novel, extracorporeal method of successfully eradicating the multidrug-resistant pathogen using a tuned laser in conjunction with metallic nanoparticles conjugated to a patent-pending non-neutralizing, high-affinity antibody. Halberd previously demonstrated its patent-pending extracorporeal laser eradication by successfully eliminating Escherichia coli and antibiotic resistant strains of Gram-Negative bacteria.
Candida auris is a serious and growing public health threat. It is a multidrug-resistant fungal pathogen that can cause serious infections and is associated with high mortality rates, particularly in immunocompromised patients.
See CBS News report:
from the pr on 1-19-23
ws this the reason why=Our ultimate objective,” according to Paul Beasant, Chairman of the Board of Directors, ”is to manufacture graphene-enhanced materials and products for public consumption, such as custom printed sports & riding helmets. However, for now our efforts are focused on lightweight, protective, 3D-printed gear for military and law enforcement applications.”
Nova Graphene graphenes and novel additive formulations are integrated into the production processes of other products to make them stronger, harder, lighter, and more fire-resistant.
CEO Gabe Vlad reports: “The ballistic plate will also integrate with a local network of devices to provide power and data for all peripherals. My previous experience serving as CTO of Lightspeed in the context of a US Army proposal where power, data and light was provided as woven articles within the man-wearables for total integration of all electronic gear and armor will serve well in this new venture.”
See the following video, providing enlightening information on the history of protective armor:
5s 5s,u said some
halb
halb-OTC DISCLOSURE & NEWS SERVICE
Halberd Demonstrates Eradication of CDC Provided Antibiotic Resistant Bacteria
Press Release | 02/08/2023
Youngstown State University (YSU) Professors and Student Scholars Successfully Conduct Research Testing
JACKSON CENTER, PA / ACCESSWIRE / February 8, 2023 / Halberd Corporation (OTC PINK:HALB) has demonstrated its patent-pending extracorporeal laser eradication process is capable of eliminating antibiotic resistant strains of CDC provided bacteria samples. Previously, Halberd demonstrated success in eliminating Escherichia coli and other Gram-Negative bacteria at Youngstown State University (YSU). The research is being carried out by Dr. Chester Cooper and Dr. W. Gregg Sturrus with the assistance of student scholar lab assistants
Dr. Cooper, Professor, Department of Chemical and Biological Sciences at YSU stated, "The students have become quite adept at conjugating the necessary antibodies to the metallic nanoparticles and combining them with the bacteria under test, in preparation for laser exposure in Dr. Sturrus' lab. The students, with appropriate training, have been able to meticulously prepare the various strains of bacteria for laser exposure as well as assessing the degree of bacteria elimination after laser exposure. The really exciting aspect of this research is that we have been able to eliminate a variety of bacteria using the same antibody due to its affinity to a wide range of bacteria."
"The enthusiasm of these students and dedication to the project is nothing like I have ever seen," added Dr. Sturrus, Chair and Professor, Physics, Astronomy Geology and Earth Science Department. The Halberd research project to extracorporeally eradicate target antigens through laser micro-heating provides the students with a great opportunity to experience real world applications of the concepts that they learn in the classroom."
William A. Hartman, Halberd's Chairman, President & CEO commented, "The significance of Halberd's achievements in eradicating antibiotic resistant bacteria in ten minutes or less exposure to laser emissive energy compares favorably to the current standard of care of oral or injected antibiotic administration for up to ten days of required treatment. We intend to continue demonstrating the superiority of Halberd's technology by eradicating additional strains of Escherichia coli, Candida auris, Salmonella, Shigella, pneumococcus, etc. We believe that Halberd's patented advancement in the treatment of antibiotic-resistant bacteria could revolutionize future medicine worldwide, and we intend to prove it. We have yet to encounter an antigen that we have not been able to successfully eradicate with our patented process. Moreover, we have the flexibility of a multiplicity of eradication methods - laser, chemical bonding and radio frequency, each safely administered extracorporeally."
To get the latest news on Halberd's exciting developments, including our ongoing disease eradication accomplishments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/)
For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
OTC DISCLOSURE & NEWS SERVICE.HALB
Halberd Demonstrates Eradication of CDC Provided Antibiotic Resistant Bacteria
Press Release | 02/08/2023
Youngstown State University (YSU) Professors and Student Scholars Successfully Conduct Research Testing
JACKSON CENTER, PA / ACCESSWIRE / February 8, 2023 / Halberd Corporation (OTC PINK:HALB) has demonstrated its patent-pending extracorporeal laser eradication process is capable of eliminating antibiotic resistant strains of CDC provided bacteria samples. Previously, Halberd demonstrated success in eliminating Escherichia coli and other Gram-Negative bacteria at Youngstown State University (YSU). The research is being carried out by Dr. Chester Cooper and Dr. W. Gregg Sturrus with the assistance of student scholar lab assistants
Dr. Cooper, Professor, Department of Chemical and Biological Sciences at YSU stated, "The students have become quite adept at conjugating the necessary antibodies to the metallic nanoparticles and combining them with the bacteria under test, in preparation for laser exposure in Dr. Sturrus' lab. The students, with appropriate training, have been able to meticulously prepare the various strains of bacteria for laser exposure as well as assessing the degree of bacteria elimination after laser exposure. The really exciting aspect of this research is that we have been able to eliminate a variety of bacteria using the same antibody due to its affinity to a wide range of bacteria."
"The enthusiasm of these students and dedication to the project is nothing like I have ever seen," added Dr. Sturrus, Chair and Professor, Physics, Astronomy Geology and Earth Science Department. The Halberd research project to extracorporeally eradicate target antigens through laser micro-heating provides the students with a great opportunity to experience real world applications of the concepts that they learn in the classroom."
William A. Hartman, Halberd's Chairman, President & CEO commented, "The significance of Halberd's achievements in eradicating antibiotic resistant bacteria in ten minutes or less exposure to laser emissive energy compares favorably to the current standard of care of oral or injected antibiotic administration for up to ten days of required treatment. We intend to continue demonstrating the superiority of Halberd's technology by eradicating additional strains of Escherichia coli, Candida auris, Salmonella, Shigella, pneumococcus, etc. We believe that Halberd's patented advancement in the treatment of antibiotic-resistant bacteria could revolutionize future medicine worldwide, and we intend to prove it. We have yet to encounter an antigen that we have not been able to successfully eradicate with our patented process. Moreover, we have the flexibility of a multiplicity of eradication methods - laser, chemical bonding and radio frequency, each safely administered extracorporeally."
To get the latest news on Halberd's exciting developments, including our ongoing disease eradication accomplishments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/)
For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
OTC DISCLOSURE & NEWS SERVICE
Halberd Demonstrates Eradication of CDC Provided Antibiotic Resistant Bacteria
Press Release | 02/08/2023
Youngstown State University (YSU) Professors and Student Scholars Successfully Conduct Research Testing
JACKSON CENTER, PA / ACCESSWIRE / February 8, 2023 / Halberd Corporation (OTC PINK:HALB) has demonstrated its patent-pending extracorporeal laser eradication process is capable of eliminating antibiotic resistant strains of CDC provided bacteria samples. Previously, Halberd demonstrated success in eliminating Escherichia coli and other Gram-Negative bacteria at Youngstown State University (YSU). The research is being carried out by Dr. Chester Cooper and Dr. W. Gregg Sturrus with the assistance of student scholar lab assistants
Dr. Cooper, Professor, Department of Chemical and Biological Sciences at YSU stated, "The students have become quite adept at conjugating the necessary antibodies to the metallic nanoparticles and combining them with the bacteria under test, in preparation for laser exposure in Dr. Sturrus' lab. The students, with appropriate training, have been able to meticulously prepare the various strains of bacteria for laser exposure as well as assessing the degree of bacteria elimination after laser exposure. The really exciting aspect of this research is that we have been able to eliminate a variety of bacteria using the same antibody due to its affinity to a wide range of bacteria."
"The enthusiasm of these students and dedication to the project is nothing like I have ever seen," added Dr. Sturrus, Chair and Professor, Physics, Astronomy Geology and Earth Science Department. The Halberd research project to extracorporeally eradicate target antigens through laser micro-heating provides the students with a great opportunity to experience real world applications of the concepts that they learn in the classroom."
William A. Hartman, Halberd's Chairman, President & CEO commented, "The significance of Halberd's achievements in eradicating antibiotic resistant bacteria in ten minutes or less exposure to laser emissive energy compares favorably to the current standard of care of oral or injected antibiotic administration for up to ten days of required treatment. We intend to continue demonstrating the superiority of Halberd's technology by eradicating additional strains of Escherichia coli, Candida auris, Salmonella, Shigella, pneumococcus, etc. We believe that Halberd's patented advancement in the treatment of antibiotic-resistant bacteria could revolutionize future medicine worldwide, and we intend to prove it. We have yet to encounter an antigen that we have not been able to successfully eradicate with our patented process. Moreover, we have the flexibility of a multiplicity of eradication methods - laser, chemical bonding and radio frequency, each safely administered extracorporeally."
To get the latest news on Halberd's exciting developments, including our ongoing disease eradication accomplishments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/)
For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
NEWS
Nova Graphene Ballistics (OTC PINK: BIEI) Retains Award Winning Communication Firm To Expand Public Messaging
(via NewsDirect)
McapMediaWire-- Nova-Graphene Ballistics, Inc. (OTC: BIEI), (NG Ballistics) (pending the name change from “Premier Biomedical Inc.”) announced today that it has retained Black Ram Media Group Inc to advise on public relations, create a new website and develop the brand for the company’s new name, Nova Graphene Ballistics, Inc.
Black Ram Media Group Inc, named Corporate Vision’s Best Political/Corporate Communications Experts-Eastern Canada, will be responsible for creating a comprehensive communications strategy and a new website that will effectively communicate the company’s mission and its innovative products.
“We are thrilled to have Black Ram Media on board to help us communicate our message to the public,” said Paul Beasant, Chairman of the Board of Nova Graphene Ballistics, Inc. “Their expertise in corporate communications and public relations will be invaluable in positioning us as a leading player in the body armor market.”
Daniela Siggia, Black Ram strategist, added: “Nova Graphene Ballistics is an exciting company that is doing innovative work in the body armor space. We are thrilled to be working with them to help them tell their story and build their brand.”
About Nova Graphene Ballistics, Inc:
Nova Graphene Ballistics, Inc, formerly known as Premier Biomedical Inc, is a leading provider of advanced body armor utilizing cutting-edge technology to design and manufacture armor that is not only stronger and lighter, but also fully customizable to the wearer’s unique requirements.
About Black Ram Media Group Inc:
Black Ram Media Group Inc is an award-winning communications firm that specializes in creating effective communications strategies for companies and organizations in a variety of industries. They were named Corporate Vision’s Best Political/Corporate Communications Experts-Eastern Canada.
For more information, please contact:
Black Ram Media Group Inc.:
info@blackrammedia.com
To get the latest news on the exciting developments from Premier Biomedical Inc. (OTC:BIEI), now known as Nova Graphene Ballistics, Inc., subscribe by submitting to: https://ngballistics.com/contact/</b>
For more information, please contact us at:
info@novagrapheneballistics.com
Our website (work in process):
https://ngballistics.com/</b>
Twitter: @PremierBiomedic
https://twitter.com/PremierBiomedic</b>
Physical address: 2409 Sycamore Drive, Knoxville, TN 37921, a 12,000 sq ft light industrial facility.
About Nova Graphene Ballistics, Inc. (OTC: BIEI), engaged in a holding company reorganization so that the parent company, renamed from “Premier Biomedical Inc.”, has no convertible debentures outstanding. As a result, the successor issuer public company, Nova Graphene Ballistics, Inc., has nearly no debt. The predecessor issuer’s debt remains in the original company, now a subsidiary of the publicly traded company. The Company is traded on the OTC Market, in full compliance with OTC Market reporting requirements. Nova Graphene Ballistics, Inc. is in the process of a single corporate action – changing its name with FINRA and thus OTC Markets. Its articles of incorporation prohibit a reverse split. It is involved in the development of sophisticated products utilizing the unique characteristics of graphene, partnering with related corporations: Nova Graphene Inc. and Nova Graphene Canada.
Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). The Company’ cautions our readers that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time the statements are made. These statements may address issues that involve significant risks, uncertainties and associated estimates made by management. Actual results could differ materially from current projections or implied results. Nova Graphene Ballistics, Inc. (NG Ballistics) (OTC: “BIEI“), whose name is being changed from Premier Biomedical Inc., undertakes no obligation to revise these statements following the date of this news release.
<B>CONTACT DETAILS</B><B>CONTACT DETAILS</B>
Nova Graphene Ballistics
Paul Beasant
$1.00 is a long way to go,$$$$$$$$$$$
i have 1 million shs
Premier Biomedical Inc. (OTC PINK: BIEI), now known as Nova Graphene Ballistics, Inc., Releases its Graphene Ballistic Plate Production Approach
Premier, N/K/A Nova Graphene Ballistics, Inc., commences development of this Proprietary Technology for Lightweight, Protective, Ballistic Plate Production with proprietary CarbonEra™ Graphene for Implementation with Novel 3D Printing Filaments in Knoxville
Knoxville, TN, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Nova Graphene Ballistics, Inc. (OTC PINK: BIEI), (“pending the name change from “Premier Biomedical Inc.”), announces the following steps, in pursuit of its first initiative 3D-printed Graphene Ballistic Plate Production, including the prototype, with regard to novel graphene production. With the timing of completing each step to be reported shortly, some of the highlights are as follows:
• Novel 3D printing filaments.
• Customized set-up & modifications to our high-temperature printers to enable optimized performance.
• Proprietary software to convert 3D body & equipment scans to printable ballistic plate files.
• Novel internal plate architecture.
• Marriage of the custom 3D-printed base plate with an integrated strike face (designed to tumble incoming rounds for efficient energy dispersion).
• Prototype delivery to DARPA, consistent with our white paper.
”Our ultimate objective,” according to Paul Beasant, Chairman of the Board of Directors, ”is to manufacture graphene-enhanced materials and products for public consumption, such as custom printed sports & riding helmets. However, for now our efforts are focused on lightweight, protective, 3D-printed gear for military and law enforcement applications.”
Nova Graphene graphenes and novel additive formulations are integrated into the production processes of other products to make them stronger, harder, lighter, and more fire-resistant.
CEO Gabe Vlad reports: “The ballistic plate will also integrate with a local network of devices to provide power and data for all peripherals. My previous experience serving as CTO of Lightspeed in the context of a US Army proposal where power, data and light was provided as woven articles within the man-wearables for total integration of all electronic gear and armor will serve well in this new venture.”
See the following video, providing enlightening information on the history of protective armor:
Halberd to Conduct Animal Tests of Nasal Spray that Blocks Negative Effects of Head Trauma
Press Release | 01/31/2023
Tests to be scheduled at Mississippi State University
JACKSON CENTER, PA / ACCESSWIRE / January 31, 2023 / Halberd Corporation (OTC PINK:HALB) confirmed that animal testing at Mississippi State University (MSU) will focus on Halberd's patent-pending nasal spray to mitigate the effects of Traumatic Brain Injury (TBI), when administered shortly after sustaining a head Injury. The work will be conducted over the next several months under the direction of Dr. Russell Carr, of the College of Veterinary Medicine.
Following Halberd's in vitro successful eradication of each known antigen associated with head trauma, including TBI, in collaboration with Youngstown State University, in vivo studies are to commence at Mississippi State University. Funding for the program has already been approved.
Head trauma initiates a cascade of overproduction of certain proteins and inflammatory cytokines in the brain. This overproduction, depending on the magnitude of the injury, often manifests itself in neurological changes in behavior, such as PTSD, aggression and suicide ideation. Halberd's triple-action nasal spray is designed to counteract these TBI-related complications by blocking the overproduction mechanism and allowing the brain to recover naturally. The benefits of such an approach in treating head injuries to military personnel, contact sports athletes and ordinary people who experience head trauma are monumental.
Dr. Mitchell S. Felder, Halberd's Chief Technology Officer and a board-certified attending neurologist stated, "We have been very impressed by the protocol for testing traumatic brain injury in animals by the professors at Mississippi State University. What sets Halberd's nasal spray treatment apart is the ability to administer the treatment soon after injury in any setting, thus reducing the potential for serious permanent neurological damage."
William A. Hartman, Chairman, President & CEO of Halberd Corporation, added, "Selecting a source for animal testing of our anti-traumatic brain injury nasal spray was a very difficult process. Many universities we met with simply didn't have the process, experience, or expertise to conduct the tests in a manner that would yield our desired results. Mississippi State University has developed the procedures and delivered a test protocol that meets Halberd's rigid specifications. We look forward to a successful program with Mississippi State University."
To get the latest news on Halberd's exciting developments, subscribe by submitting this.
(https://halberdcorporation.com/contact-us/)
For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
Twitter:@HalberdC
About Mississippi State University College of Veterinary Medicine (CVM).
Mississippi State University College of Veterinary Medicine (MSU CVM) was founded in 1974 The CVM has a total of six locations and serves all 82 counties in Mississippi as well as the entire Southeastern United States. The College's main campus is in Starkville and includes the Wise Center, which houses its main teaching hospital, the Animal Health Center. The MSU CVM Department of Comparative Biomedical Sciences faculty and staff represent the basic scientific disciplines required for education of veterinarians. MSU CVM is committed to an ethical approach to treating animals with a genuine passion and drive.
About Halberd Corporation.
Halberd Corporation (OTC PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Since its restructuring in April of 2020, Halberd has obtained exclusive worldwide rights to three issued patents and has filed 22 related provisional, PCT, or utility patent applications to enhance its value to its stockholders and to attract the interests of potential development partners.
Safe Harbor Notice
yes he is
its 30 million.of the net
hear,hear u didnt hear it all
biei also the holding company for halb
had biei and halb on my watch list since 2020 0f march,$$$$$$$$$$$$$$$$$
had biei and halb on my watch list since 2020 0f march,$$$$$$$$$$$$$$$$$
otc market
go to otc marke,hit news go back to may 20,2020,read all the news,and u will find it,like i did halb had a contract with biei for 30 million $$$,if halb would discover a cure or treatment for things they r working on
See new Tweets
Conversation
Premier Biomedical
@PremierBiomedic
Premier Biomedical, Halberd and Gold River Agree to Work Jointly to Develop Premier’s Patented Extracorporeal Technology on COVID-19 Treatment And Proprietary Anti-Addiction PatchTM
YES hopefuly soon
WRONG,he said over the next few months,not in a few months,
$BIEI new address ties back to Carbon Rivers ??
Seems Nova Graphene & Carbon Rivers are coming together to form one entity (Nova Graphene Ballistics)
So basically this merger is two companies merging into one entity, and that entity is coming into $BIEI
still need annual report to be updated
r trying to set things right
yes,looks like it to me 2,looks like they r trying to set things right,
12/27/2022 -annual report should be coming out,maybe late,means tomorow mabe